{"id":9109,"date":"2025-10-27T21:53:38","date_gmt":"2025-10-27T18:53:38","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9109"},"modified":"2025-10-27T21:53:38","modified_gmt":"2025-10-27T18:53:38","slug":"pediatric-heart-failure-2025-day-2-expert-reflections","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/pediatric-heart-failure-2025-day-2-expert-reflections\/","title":{"rendered":"Pediatric Heart Failure 2025 \u2013 Day-2 Expert Reflections"},"content":{"rendered":"
Pediatric Heart Failure 2025 \u2013 Day-2 Expert Reflections<\/div>\n
<\/div>\n
Source: Jordan Cardiac Society Conference \u2013Key insights and follow-up commentary from the second-day pediatric sessions and national roundtable discussions on heart failure in children.<\/div>\n
<\/div>\n
1.\u2060 \u2060Etiologic Insights \u2013 Pediatric vs Adult HF<\/div>\n
\u2022 Ischemia is rare in children: Pediatric HF is overwhelmingly non-ischemic, caused mainly by congenital or structural defects.<\/span><\/div>\n
Adult HF, in contrast, is dominated by ischemic heart disease (\u2248 70%) and hypertension.<\/div>\n
\u2022 Most common pediatric causes:<\/span><\/div>\n
Congenital heart disease (60\u201370%), cardiomyopathies (20\u201325%), myocarditis (10\u201315%), rheumatic and Kawasaki disease, and chemotherapy-related (anthracycline) cardiomyopathy.<\/div>\n
Less frequent: arrhythmia-induced, endocrine\/metabolic, or infiltrative disorders.<\/div>\n
\u2022 Clarification:<\/span><\/div>\n
\u2022 Rheumatic heart disease does not refer to autoimmune \u201crheumatism\u201d but rather to post-streptococcal valvular inflammation following Group A Streptococcus throat infection \u2014 leading to chronic mitral and aortic valve damage and later HF.<\/span><\/div>\n
\u2022 SLE (Systemic Lupus Erythematosus), on the other hand, is a true autoimmune disorder that may cause myocarditis or pericarditis; it is much rarer but often treatable with immunosuppressive therapy.<\/span><\/div>\n
\u2022 Distinctive pattern: Pediatric HF often results from volume\/pressure overload or myocardial inflammation, not coronary atherosclerosis.<\/span><\/div>\n
Many cases are potentially reversible with timely intervention \u2014 unlike the chronic degenerative course typical in adults.<\/div>\n
<\/div>\n
2.\u2060 \u2060Clinical Staging Adapted to Pediatrics<\/div>\n
\u2022 Ross Classification (Infants & Young Children): focuses on feeding intolerance, tachypnea, diaphoresis, and growth failure.<\/span><\/div>\n
\u2022 Modified NYHA (for Older Children): evaluates limitation during school or play activities rather than occupational effort.<\/span><\/div>\n
\u2022 Difference from Adult AHA\/ACC Staging (A\u2013D):<\/span><\/div>\n
\u2022\u2060\u00a0 \u2060Pediatric systems are symptom-based, emphasizing growth and developmental parameters.<\/div>\n
\u2022\u2060\u00a0 \u2060Adult staging is disease-progression-based, following risk \u2192 structural change \u2192 symptomatic \u2192 refractory HF.<\/div>\n
\u2022\u2060\u00a0 \u2060Pediatric staging guides daily care and growth monitoring, while adult staging defines long-term prognosis and therapy planning.<\/div>\n
<\/div>\n
3.\u2060 \u2060Diagnostic Refinements<\/div>\n
\u2022 Echocardiography: the cornerstone for assessing chamber size, systolic\/diastolic function, and valves.<\/span><\/div>\n
\u2022 Traditional EF: measures the percentage of blood pumped out of the ventricle. EF may remain normal even when the myocardium is already weakening.<\/span><\/div>\n
\u2022 GLS (Global Longitudinal Strain): detects this early decline before EF falls, serving as an early-warning sign for subtle LV dysfunction.<\/span><\/div>\n
It measures how strongly the heart muscle contracts along its length\u2014from base to apex.<\/div>\n
When the heart beats, fibers shorten and twist lengthwise\u2014like a sponge squeezed from both ends.<\/div>\n
GLS tracks this motion by following tiny \u201cspeckles\u201d on the heart wall using speckle-tracking echocardiography.<\/div>\n
\u2022 This technique became practical with the spread of 3-D \/ 4-D echocardiography, allowing quantitative detection of early dysfunction.<\/span><\/div>\n
\u2022 Cardiac MRI (CMR): identifies fibrosis or edema and differentiates myocarditis vs cardiomyopathy, guiding prognosis and transplant timing.<\/span><\/div>\n
\u2022 Biomarkers: BNP and NT-proBNP correlate with severity and should be trended serially.<\/span><\/div>\n
<\/div>\n
4.\u2060 \u2060Pharmacologic & Device Updates<\/div>\n
\u2022 ARNI (Sacubitril\/Valsartan): FDA-approved \u2265 1 year; cornerstone therapy for pediatric HFrEF when tolerated.<\/span><\/div>\n
\u2022 \u03b2-Blockers & MRAs: remain mainstays; dosing individualized by weight and target HR.<\/span><\/div>\n
\u2022 Ivabradine: FDA-approved \u2265 6 months; for symptomatic children in sinus rhythm with HR > 100 bpm despite \u03b2-blocker\u2014reflecting the higher physiologic pediatric HR compared with adult targets (\u2248 60\u201370 bpm).<\/span><\/div>\n
\u2022 SGLT2 Inhibitors: still investigational in pediatrics; not yet part of the \u201cfour-pillar\u201d therapy. Consider only after standard triple therapy (ARNI\/ACEI + \u03b2-blocker + MRA) in expert centers.<\/span><\/div>\n
\u2022 ECMO \/ VAD: ECMO for acute decompensation or cardiogenic shock before multi-organ failure; VADs (e.g., Berlin Heart EXCOR, HeartMate III) as long-term bridges to recovery or transplant.<\/span><\/div>\n
<\/div>\n
5.\u2060 \u2060Supportive and Preventive Care<\/div>\n
\u2022 Psychosocial and transition-of-care programs are vital, especially for adolescents moving to adult clinics.<\/span><\/div>\n
\u2022 Vaccination bundle: influenza, pneumococcus, RSV (where eligible).<\/span><\/div>\n
\u2022 Nutrition: address both caloric needs and micronutrient deficiencies (iron, vitamin D).<\/span><\/div>\n
\u2022 Home monitoring:<\/span><\/div>\n
\u2022\u2060\u00a0 \u2060Home scale: daily weight tracking; > 1\u20132 kg gain in 48 h signals fluid retention.<\/div>\n
\u2022\u2060\u00a0 \u2060Tele-HF tools: remote SpO\u2082 and ECG upload for early detection of decompensation.<\/div>\n
<\/div>\n
6.\u2060 \u2060National Recommendations and Future Priorities<\/div>\n
\u2022 Establish a Jordan Pediatric HF Registry linked with adult registries for longitudinal data.<\/span><\/div>\n
\u2022 Launch district HF clinics with certified HF nurses and coordinators.<\/span><\/div>\n
\u2022 Create standardized transfer pathways (door-to-VAD \/ door-to-transplant) to ensure timely access to advanced care.<\/span><\/div>\n
\u2022 Strengthen public awareness campaigns for early recognition of pediatric cardiac symptoms.<\/span><\/div>\n
\u2022 Integrate tele-HF monitoring into national quality-improvement initiatives.<\/span><\/div>\n
<\/div>\n
7.\u2060 \u2060Key Takeaway<\/div>\n
<\/div>\n
Pediatric heart failure differs fundamentally from adult HF in etiology, physiology, and reversibility.<\/div>\n
The use of GLS and 3-D \/ 4-D echocardiography, alongside pediatric-specific staging and unified national pathways, represents a transformative step in modern cardiac care.<\/div>\n
The Jordan Cardiac Society\u2019s Pediatric HF Program establishes a regional model for standardized, multidisciplinary management\u2014ensuring that every child receives timely, evidence-based, and compassionate treatment.<\/div>\n","protected":false},"excerpt":{"rendered":"

Pediatric Heart Failure 2025 \u2013 Day-2 Expert Reflections Source: Jordan Cardiac Society Conference \u2013Key insights and follow-up commentary from the second-day pediatric sessions and national roundtable discussions on heart failure in children. 1.\u2060 \u2060Etiologic Insights \u2013 Pediatric vs Adult HF \u2022 Ischemia is rare in children: Pediatric HF is overwhelmingly non-ischemic, caused mainly by congenital […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9109","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9109"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9109\/revisions"}],"predecessor-version":[{"id":9110,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9109\/revisions\/9110"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}